Begin main content

Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness

Last updated: November 7, 2017
Project Number: RB1154-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of the off-label use of intravenous immunoglobulin for the treatment of solid organ transplant rejection, paraneoplastic disorders, or recurrent miscarriage?

Key Message

Five systematic reviews, three randomized controlled trials, and nine non-randomized studies were identified regarding the off-label use of intravenous immunoglobulin for the treatment of solid organ transplant rejection, paraneoplastic disorders, or recurrent miscarriage.